Workflow
润都股份(002923) - 2019 Q1 - 季度财报
Rundu PharmaRundu Pharma(SZ:002923)2019-04-22 16:00

Financial Performance - The company's revenue for Q1 2019 was ¥340,703,319.84, representing a 53.35% increase compared to ¥222,172,370.14 in the same period last year[7] - Net profit attributable to shareholders was ¥28,986,836.25, up 45.23% from ¥19,959,945.38 year-on-year[7] - Total revenue for Q1 2019 reached ¥340.70 million, a 53.35% increase compared to ¥222.17 million in Q1 2018, primarily due to expanded sales scale[17] - Net profit for Q1 2019 was ¥28,986,836.25, representing a 45.2% increase from ¥19,959,945.38 in the same period last year[41] - The company reported a total comprehensive income of CNY 28,986,836.25 for the period, compared to CNY 19,959,945.38 in the prior year[42] Cash Flow - The net cash flow from operating activities increased by 140.12% to ¥46,113,250.90, compared to ¥19,204,268.11 in the previous year[7] - Cash flow from operating activities improved by 140.12% to ¥46.11 million in Q1 2019, compared to ¥19.20 million in Q1 2018, driven by increased sales and cash collection[19] - The total cash inflow from operating activities was CNY 290,526,021.05, compared to CNY 207,473,629.39 in the previous year, showing strong operational performance[50] - The company's operating cash flow for the current period was CNY 31,850,709.77, a significant increase from CNY 5,968,627.52 in the previous period, reflecting a growth of approximately 433%[52] - The cash flow from sales of goods and services was CNY 175,277,954.43, compared to CNY 115,120,990.21 in the previous period, reflecting a growth of approximately 52%[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,224,803,039.44, a 7.59% increase from ¥1,138,419,861.16 at the end of the previous year[7] - The total liabilities of the company were CNY 324,521,650.99, up from CNY 267,125,308.96, which is an increase of approximately 21.43%[32] - The company's current assets totaled CNY 830,075,269.77, up from CNY 774,755,173.40 at the end of 2018, indicating an increase of about 7.13%[31] - Total liabilities increased to ¥234,822,999.92 in Q1 2019, compared to ¥188,865,203.01 in Q1 2018, reflecting a rise of 24.4%[37] Expenses - Operating costs increased by 43.91% to ¥96.56 million in Q1 2019 from ¥67.10 million in Q1 2018, attributed to the growth in sales[17] - Sales expenses increased by 62.86% to ¥165.04 million in Q1 2019 from ¥101.34 million in Q1 2018, due to increased marketing and academic promotion efforts[17] - Management expenses decreased by 40.88% to ¥10.77 million in Q1 2019, down from ¥18.21 million in Q1 2018, as last year's figures included significant listing expenses[17] - The total operating costs for Q1 2019 were ¥315,977,992.42, an increase of 58.5% from ¥199,318,778.80 in Q1 2018[39] Research and Development - R&D expenses surged by 226.06% to ¥34.76 million in Q1 2019, up from ¥10.66 million in Q1 2018, reflecting increased investment in research and development[17] - Research and development expenses for Q1 2019 were ¥34,762,737.02, which is a substantial increase of 226.5% compared to ¥10,661,599.43 in Q1 2018[39] - Research and development expenses increased significantly to CNY 34,001,850.74, up from CNY 10,661,599.43, indicating a focus on innovation[45] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,318[11] - The company's equity remained stable at CNY 120,000,000.00, unchanged from the previous reporting period[32] - The company's total equity attributable to shareholders reached ¥897,963,489.46, up from ¥874,912,175.48, indicating a growth of 2.7%[38] Government Subsidies and Other Income - The company received government subsidies amounting to ¥4,727,107.76 during the reporting period[8] - Other income rose by 69.35% to ¥4.73 million in Q1 2019, compared to ¥2.79 million in Q1 2018, due to higher government subsidies received[17] - The company recorded other income of CNY 4,727,107.76, up from CNY 2,791,268.70, contributing positively to the overall financial performance[45] Investment Activities - Investment activities generated a net cash outflow of ¥39.05 million in Q1 2019, a 74.79% increase in outflow compared to ¥22.34 million in Q1 2018, mainly due to increased fixed asset investments[19] - The company incurred a total of CNY 372,845,750.41 in cash outflows from investing activities, indicating ongoing investments in growth initiatives[50] - The company received CNY 291,000,000.00 from the recovery of investments, indicating strong investment management[52]